Summit Therapeutics (SMMT) News Today $23.06 +1.71 (+7.99%) As of 10:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SMMT Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period APEIRON CAPITAL Ltd Takes $25.56 Million Position in Summit Therapeutics PLC $SMMTOctober 12 at 5:04 AM | marketbeat.comSummit Therapeutics' (SMMT) "Sell (D-)" Rating Reaffirmed at Weiss RatingsOctober 9, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTOctober 8, 2025 | prnewswire.comWhere is Summit Therapeutics (SMMT) Headed According to Analysts?October 8, 2025 | finance.yahoo.com14 Biotech Stocks with High PotentialOctober 7, 2025 | insidermonkey.comSummit Therapeutics PLC (NASDAQ:SMMT) Receives Average Recommendation of "Hold" from BrokeragesOctober 7, 2025 | americanbankingnews.comSummit Therapeutics PLC (NASDAQ:SMMT) Given Average Recommendation of "Hold" by BrokeragesOctober 7, 2025 | marketbeat.comPublic Employees Retirement System of Ohio Makes New Investment in Summit Therapeutics PLC $SMMTOctober 6, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT), Summit Therapeutics (SMMT) and United Therapeutics (UTHR)October 5, 2025 | theglobeandmail.com1 Monster Stock in the Making to Buy and HoldOctober 5, 2025 | fool.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTOctober 3, 2025 | prnewswire.comA Look at Summit Therapeutics (SMMT) Valuation Following Phase III Trial Setback and Legal InvestigationOctober 2, 2025 | finance.yahoo.comH.C. Wainwright Reaffirms Price Target for Summit Therapeutics (SMMT) After Ivonescimab MilestonesOctober 2, 2025 | msn.comSummit Therapeutics Inc. (SMMT) Highlights Ivonescimab Progress at WCLC 2025October 1, 2025 | msn.comSummit Therapeutics (NASDAQ:SMMT) Shares Pass Below 50-Day Moving Average - What's Next?October 1, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTSeptember 28, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTSeptember 24, 2025 | globenewswire.comHARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in ...September 24, 2025 | finance.yahoo.comHARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in ...September 24, 2025 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTSeptember 23, 2025 | prnewswire.comWealth Management Partners LLC Cuts Stock Position in Summit Therapeutics PLC $SMMTSeptember 21, 2025 | marketbeat.comVoya Investment Management LLC Lowers Stock Position in Summit Therapeutics PLC $SMMTSeptember 20, 2025 | marketbeat.comJim Cramer on Summit Therapeutics: “We’re Going to Have to Move On”September 19, 2025 | msn.comBarclays Upgrades Summit Therapeutics (NASDAQ:SMMT) to "Strong Sell"September 19, 2025 | marketbeat.comRockland Trust Co. Buys Shares of 400,000 Summit Therapeutics PLC $SMMTSeptember 19, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTSeptember 18, 2025 | prnewswire.comSummit Therapeutics (NASDAQ:SMMT) Coverage Initiated at BarclaysSeptember 18, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Receives Buy Rating from HC WainwrightSeptember 17, 2025 | marketbeat.comFocus Partners Wealth Boosts Stake in Summit Therapeutics PLC $SMMTSeptember 17, 2025 | marketbeat.comSummit Therapeutics Inc. Investigated by the Portnoy Law FirmSeptember 16, 2025 | globenewswire.comInsiders Are Aggressively Buying These 5 StocksSeptember 16, 2025 | 247wallst.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Up Following Insider Buying ActivitySeptember 14, 2025 | marketbeat.comSummit Therapeutics PLC (NASDAQ:SMMT) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 14, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) CEO Robert Duggan Acquires 333,394 SharesSeptember 13, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) CEO Mahkam Zanganeh Buys 333,394 SharesSeptember 13, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTSeptember 13, 2025 | prnewswire.comSiren L.L.C. Takes $13.41 Million Position in Summit Therapeutics PLC $SMMTSeptember 13, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.2% - Should You Sell?September 12, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) CEO Robert Duggan Purchases 5,000 SharesSeptember 12, 2025 | insidertrades.comSummit Therapeutics (SMMT) Is Down 21.0% After Mixed HARMONi Trial Data Raises Global Approval QuestionsSeptember 10, 2025 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTSeptember 10, 2025 | globenewswire.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down - Here's What HappenedSeptember 10, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Receives "Overweight" Rating from Cantor FitzgeraldSeptember 10, 2025 | marketbeat.comSummit Therapeutics' (SMMT) Buy Rating Reiterated at HC WainwrightSeptember 10, 2025 | marketbeat.comCORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law FirmSeptember 9, 2025 | globenewswire.comSummit Therapeutics Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 24, 2025 Deadline to file Lead Plaintiff Motion.September 9, 2025 | globenewswire.comPolar Asset Management Partners Inc. Trims Holdings in Summit Therapeutics PLC $SMMTSeptember 9, 2025 | marketbeat.com538,000 Shares in Summit Therapeutics PLC $SMMT Acquired by Adage Capital Partners GP L.L.C.September 9, 2025 | marketbeat.comSummit Therapeutics falls -24.1%September 8, 2025 | msn.comSummit Therapeutics (SMMT) WCLC Update Call (Transcript)September 8, 2025 | seekingalpha.com Get Summit Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SMMT Media Mentions By Week SMMT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SMMT News Sentiment▼0.770.77▲Average Medical News Sentiment SMMT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SMMT Articles This Week▼99▲SMMT Articles Average Week Get the Latest News and Ratings for SMMT and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Summit Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Merck & Co., Inc. News Today argenex News Today Takeda Pharmaceutical News Today BeOne Medicines News Today Insmed News Today BioNTech News Today Teva Pharmaceutical Industries News Today Genmab A/S News Today Ascendis Pharma A/S News Today Dr. Reddy's Laboratories News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SMMT) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Summit Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
